Russian researchers from Moscow Institute of Physics and Technology, Sechenov University, National Medical Research Center of Oncology named after N.N. Blokhin, and other institutions have completed a clinical study using RNA analysis of tumors for personalized cancer treatment. The study involved 239 patients with solid tumors, where drugs recommended by the platform were prescribed to 59% of participants, showing better results than traditional methods.
The research demonstrated that analyzing the activity of target genes in tumors can predict treatment effectiveness, even in the absence of standard clinically significant mutations. The National Medical Research Center of Oncology named after N.N. Blokhin platform provides personalized therapy recommendations, enhancing treatment efficacy.
Professor Anton Buzdin stated, “This innovative method allows precise calculation of target gene activity in tumors and predicts the effectiveness of over 170 drugs for individual patients.” Patients treated based on these recommendations lived an average of 10 months longer than those receiving standard treatments, despite most being in advanced stages of the disease.
